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CD95 (Fas/Apo-1) is a 48-kDa Type I membrane protein and a
prototypic member of the nerve growth factor/tumour necrosis
factor receptor superfamily (Nagata, 1994). CD95, which is
widely expressed in normal and malignant cells, and CD95 ligand
are a set of regulatory components in the immune system.
Activation of CD95 by CD95 ligand results in apoptosis of many
cell types, and this process has been shown to play a critical role in
the maintenance of immunological homeostasis and peripheral
tolerance (Nagata, 1994).
In addition to membrane-anchored CD95, soluble CD95
(sCD95), generated by alternative mRNA splicing, can antagonize
cell-surface CD95 function (Nagata, 1994). That is, serum sCD95
may suppress apoptosis of cancer cells by blocking CD95 ligand
on lymphocytes and affect tumour progression. The biological
activity of sCD95 secreted by osteosarcoma cells was demon-
strated by the ability of osteosarcoma supernatants to protect the
sensitive T-cell line Jurkat from anti-CD95-mediated apoptosis
(Fellenberg et al, 1997). Elevated sCD95 has been reported in
haematopoietic and non-haematopoietic tumour patients, and
patients with metastasis indicated higher sCD95 levels than those
with primary disease (Midis et al, 1996). However, sCD95 has not
been examined in renal cell cancer (RCC) patients. Previously, we
reported that functional CD95 was expressed in RCC (Tomita et
al, 1996a). Here, we investigated serum sCD95 in RCC patients
and showed a correlation between higher sCD95 value and poorer
prognosis in these patients.
MATERIALS AND METHODS
Patients
Seventy-two patients with RCC were examined. Their mean age
was 60.4 years, ranging from 34 to 81 years. All patients had
undergone nephrectomy between October 1992 and March 1994.
These patients had not received chemotherapeutic or immuno-
modulatory agents before the collection of samples. Cancer tissues
were histologically graded according to the General Rule for
Clinical and Pathological Studies on Renal Cell Carcinoma
(Japanese Urological Association, Japanese Pathological Society
and Japanese Radiological Society, 1992). The grading system
includes low-grade (G1), moderate-grade (G2) and high-grade
(G3) categories according to the degree of atypia of the tumour
cells (Union Internationale Contre le Cancers (UICC), 1987).
Histological stage was determined according to the TNM classifi-
cation of malignant tumours. Survival was investigated in
December 1997, and the mean observation period was 40.6 months.
Examination of serum sCD95 and survival analysis
Serum samples were obtained from RCC patients before surgery.
Serum sCD95 level were examined using a CD95-specific double
sandwich enzyme-linked immunosorbent assay (ELISA) (soluble
Fas ELISA kit; Medical & Biological Laboratories Co. Ltd.,
Nagoya, Japan). This assay uses CD95 antibodies against two
different epitopes, one of the antibodies was polyclonal (No.
305–319 a.a) and the other monoclonal (No. 110–120 a.a) anti-
body recognized the extracellular domain. For comparison, the
serum of 17 healthy donors was also evaluated. All serum samples
were obtained with the consent of the patients and donors and
stored at –80°C until analysis.
Statistical analysis
The Mann–Whitney U-test was used to compare sCD95 levels
with the healthy donors and the RCC patients. Chi-square tests
were used to compare the sCD95 group (normal or elevated) with
T stage, M grade and histological cell type. The Cox proportional
hazards model was used in both univariate and the multivariate
analysis. Survival curves were constructed using the Kaplan–
Meier method, and differences between curves were tested using
the log-rank test.
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RESULTS
Serum sCD95 levels for RCC patients (mean = 2.95 ng ml–1)
were significantly higher than those normal controls (mean =
2.14 ng ml–1; P < 0.001). Twenty-one (29%) of 72 patients had
elevated sCD95 (elevated sCD95 group: which was defined as
more than the cut-off level, i.e. mean of healthy donors + 2 standard
deviations (s.d.): 2.93 ng ml–1; Figure 1). The correlation between
pathological factors (TNM classification, histological grade or cell
type) and sCD95 level was not statistically significant (Table 1).
The disease-specific survival rate was significantly lower in the
elevated sCD95 group than in the normal sCD95 group by the Log
rank test (Figure 2A). In each subgroup which generally have
better prognosis (Lanigan, 1995), i.e. low stage (lower than T2:
tumour confined to the kidney; Figure 2B), low grade (G1; data
not shown), clear cell subtype (not shown) or no distant metastasis
Table 1 Serum sCD95 levels in relation to pathological factors
Normal sCD95  Elevated sCD95
group group
≤T2 35 13
T3≤ 13 7
M0 42 15
M1≤ 75
G1 20 7
G2≤ 26 13
Clear cell subtype 32 15
Other subtypes 12 5
Figures are for cases with RCC.
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Figure 1 sCD95 levels in serum from RCC (renal cell carcinoma) patients
and healthy donors serum were examined by ELISA as described in
Materials and Methods. Each l l indicates one person. Median sCD95 levels
are represented by a horizontal line across each l l line. The dotted line
indicates the cut off level defined by the mean of healthy donors +2 s.d.
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Figure 2 (A) Survival of all RCC patients categorized according to the
sCD95 level. (B) Survival of RCC patients whose tumours were confined to
the kidney (øT2 tumour) categorized according to the sCD95 level. l l:
normal sCD95 group (ø 2.93 ng ml–1); n n: elevated sCD95 group. The cut off
level was described in Figure 1. The significance of the difference between
the curves was calculated by the log-rank test1650 M Kimura et al
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(not shown), the survival rate was also significantly lower in the
elevated sCD95 group than in the normal sCD95 group.
Furthermore, T category, M category, grade and serum sCD95
level were shown to be significant and independent prognostic
factors by univariate and multivariate analysis (Table 2).
DISCUSSION
We previously reported that RCC cell lines (ACHN, Caki-1, Caki-
2, A498, KH39 and KRC/Y) expressed CD95 antigen, and that
the apoptosis-inducing anti-CD95 monoclonal antibody CH-11
induced apoptosis in ACHN cells in a dose-dependent manner
(Tomita et al, 1996a). The cytotoxic effect of anti-CD95 antibody
on certain renal cell carcinoma cell lines was augmented by
pretreatment of these cells with interferon-g (Tomita et al, 1996a).
On the other hand, immunohistochemical analysis of resected
tissues from the patients with RCC revealed stronger expression of
CD95 antigen on the surface of cancer cells than that of normal
cells (Nonomura et al, 1996). These results suggested that CD95
may be a possible target for novel approaches to treatment of
human RCC.
The molecular mechanisms by which tumour cells evade apop-
totic stimuli is thought to include intracellular mechanism and
inactivation of death receptors. One of the major intracellular
mechanisms to induce apoptosis is known to include expression of
the anti-apoptotic molecules bcl-2 and bcl-xL (Boise et al, 1995;
Tomita et al, 1996a, 1996b). Other molecules including I-
FLICE/casper may inhibit apoptotic signals (Hu et al, 1997).
sCD95 were shown to antagonize both anti-CD95 and CD95
ligand-mediated cell lysis (Cheng et al, 1994; Owen-Schaub et al,
1995). sCD95 has been identified in the supernatants of activated
human lymphocytes and several tumour cell lines (Cheng et al,
1994; Owen-Schaub et al, 1995). For example, osteosarcoma cell
line LM2-p53 expresses CD95 and is resistant to the cell killing
effects of anti-CD95 (Owen-Schaub et al, 1995). The most
straightforward explanation for the antagonist activity of sCD95,
which is secreted from the cell line itself, is competition with cell-
surface CD95 for anti-CD95 or CD95 ligand binding. Since
apoptosis is known to be a critical parameter in tumorigenesis,
regulation of CD95 signalling may prove to be a primary patho-
genetic event in the evolution of some malignancies.
Elevated levels of sCD95 have been observed in the serum of
patients with autoimmune disease (Jodo et al, 1997), haematopoi-
etic (Knipping et al, 1995) and non-haematopoietic malignancies
(Midis et al, 1996). Midis et al (1996) reported that the majority of
cancer patients (including ovarian, gall bladder, lung, melanoma,
head and neck etc.) examined (58 of 67) demonstrated elevated in
sCD95 levels relative to normal controls. Among breast carcinoma
or colon carcinoma patients, those with metastatic disease demon-
strated significantly higher serum sCD95 levels than those with
primary disease (Midis et al, 1996). Presence of sCD95 detected
by ELISA in the present study may be derived from truncated
CD95 molecules (Nagata, 1994; Tomokuni et al, 1997).
Alternatively, and not mutually exclusively, CD95 was excreted by
plasma membrane-derived extracellular vesicles as reported by
Albanese et al (1998).
The mean sCD95 level of healthy donors (2.14 ng ml–1) in this
study was very close to 1.97 ng ml–1, mean sCD95 level which was
reported by Tomokuni et al (1997). Therefore, we consider that
normal controls in the present study were reliable for comparison
with RCC patients.
In the present study, serum sCD95 levels of RCC patients were
shown to be significantly higher than those of healthy donors. The
disease-specific survival rate was significantly lower in the
elevated sCD95 group than in the normal sCD95 group. Moreover,
serum sCD95 level was independent prognostic factor by multi-
variate analysis. Although the biological function of sCD95 in
patient’s serum remains to be investigated, these results suggested
that evaluation of serum sCD95 level in RCC patients may be a
useful indicator for prognosis.
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